Digital Measures of Neuropsychological Tests in AD patients
- Conditions
- Alzheimer's diseasedementia10012272
- Registration Number
- NL-OMON47745
- Lead Sponsor
- Philips Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 160
For AD patient:
1. Aged 18 and older
2. Fluent/correct speaker in Dutch
3. AD patient is able to give consent
4. AD diagnosis by a clinical specialist, such as a geriatrician or neurologist
5. Being able to perform the neuropsychological tests with an Ipad
6. AD patient living at home (not at a nursing home)
7. Date of AD diagnosis < 2yr;For healthy participant:
1. Partner of relative of a patient with AD
2. Fluent/correct speaker in Dutch
3. Able to provide informed consent
4. Aged 18 and older
For AD patient;
1. Unable or incompetent to give written informed consent
2. Severe communication deficits
3. Unable and/or unwilling to use a tablet to perform the tests
4. Medical history of neurological and/or psychiatric disorders (except for AD)
5. Mild Cognitive Impairment (MCI), vascular dementia, frontotemporal or mixed dementia diagnosis
6. Traditional neuropsychological assessment in the last 6 months
7. Bad eyesight or hearing, even with correction
8. Unable to properly use hands
9. An average alcohol consumption of 4 or more units per day
10. Use of one or more of the following types of medicine: antipsychotics, benzodiazepines, antidepressants, opioids, lithium, anti-epileptics, anti- Parkinson medication
11. Use of drugs;For healthy participant:
1. Unable or incompetent to give written informed consent
2. Medical history of neurological and/or psychiatric disorders
3. Traditional neuropsychological assessment in the last 6 months
4. Bad eyesight or hearing, even with correction
5. Unable to properly use hands
6. An average alcohol consumption of 4 or more units per day
7. Use of one or more of the following types of medicine: antipsychotics, benzodiazepines, antidepressants, opioids, lithium, anti-epileptics, anti- Parkinson medication
8. Use of drugs
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Algorithmic outcome of the automated scoring of the tests mentioned and manual<br /><br>scoring of the tests </p><br>
- Secondary Outcome Measures
Name Time Method <p>A list of measures that are significantly different for the two groups and a<br /><br>profile of combined measures that is significantly different for the two groups.<br /><br>Results of the questionnaire and interview of how the system was experienced by<br /><br>the two different groups and a list of recommendations on how the system can be<br /><br>improved for assessing people with Alzheimer*s Disease</p><br>